VTechWorks staff will be away for the Thanksgiving holiday beginning at noon on Wednesday, November 27, through Friday, November 29. We will resume normal operations on Monday, December 2. Thank you for your patience.
 

Clinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemotherapy

Simple item page
dc.contributor.authorLatifi, Maxen
dc.contributor.authorTuohy, Joanne L.en
dc.contributor.authorCoutermarsh-Ott, Sherylen
dc.contributor.authorKlahn, Shawna L.en
dc.contributor.authorLeeper, Haleyen
dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.departmentSmall Animal Clinical Sciencesen
dc.contributor.departmentBiomedical Sciences and Pathobiologyen
dc.date.accessioned2021-09-02T14:44:29Zen
dc.date.available2021-09-02T14:44:29Zen
dc.date.issued2020-09-28en
dc.date.updated2021-09-02T14:44:26Zen
dc.description.abstractBackground: Localized splenic histiocytic sarcoma (HS) in dogs is a poorly understood disease, and could have longer survival times than disseminated or hemophagocytic HS. Understanding the clinical behavior of localized splenic HS can refine treatment recommendations. Objective: To describe the clinical characteristics and outcomes of dogs with localized splenic HS. Animals: Fourteen client-owned dogs with histologically confirmed splenic HS that received splenectomy. Methods: Multi-institutional retrospective case series—medical records of dogs with splenic HS were reviewed. Dog signalment, clinicopathologic data, primary and adjuvant treatments, and outcomes were obtained. Survival data were calculated using Kaplan-Meier analysis. Dog variables such as age, weight, platelet counts were reported using descriptive statistics. The Cox proportional hazards regression method was used to determine whether potential risk factors (weight, age, albumin level, hematocrit, and platelet count) were associated with PFI. Results: Median survival time for the dogs in this study was 427 days. Twelve dogs received adjuvant lomustine-based chemotherapy. Five dogs (35.7%) were suspected or confirmed to have developed metastatic disease. Eleven dogs died of disease, 1 dog died of unrelated cause, and 2 dogs were alive at final follow-up. Conclusions and Clinical Significance: Histiocytic sarcoma in dogs can manifest as a localized form in the spleen. Dogs with localized splenic HS treated with surgery ± chemotherapy can experience survival times over a year.en
dc.description.versionPublished versionen
dc.format.extentPages 2645-2650en
dc.format.extent6 page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1111/jvim.15910en
dc.identifier.eissn1939-1676en
dc.identifier.issn0891-6640en
dc.identifier.issue6en
dc.identifier.orcidDervisis, Nikolaos [0000-0003-2869-1483]en
dc.identifier.pmid32986268en
dc.identifier.urihttp://hdl.handle.net/10919/104899en
dc.identifier.volume34en
dc.language.isoenen
dc.publisherWileyen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000573066400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectLife Sciences & Biomedicineen
dc.subjectVeterinary Sciencesen
dc.subjectdogen
dc.subjectoncologyen
dc.subjectspleenen
dc.subjectsplenectomyen
dc.subjectBINDING ADAPTER MOLECULE-1en
dc.subject0707 Veterinary Sciencesen
dc.subject.meshSpleenen
dc.subject.meshAnimalsen
dc.subject.meshDogsen
dc.subject.meshDog Diseasesen
dc.subject.meshChemotherapy, Adjuvanten
dc.subject.meshSplenectomyen
dc.subject.meshRetrospective Studiesen
dc.subject.meshHistiocytic Sarcomaen
dc.titleClinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemotherapyen
dc.title.serialJournal of Veterinary Internal Medicineen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherArticleen
dc.type.otherJournalen
dcterms.dateAccepted2020-09-15en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen
pubs.organisational-group/Virginia Tech/University Research Institutesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciencesen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciences/Durelle Scotten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemo.pdf
Size:
343.65 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Biomedical Sciences and Pathobiology
Scholarly Works, Small Animal Clinical Sciences